Funding traction Enzymlogic has recently secured a €2.2 million grant from the European Commission and the Spanish Innovation Agency (CDTI) to advance KINETICfinder technology, signaling strong validation and potential for expanded collaboration with pharmaceutical and biotech customers.

Kinetic advantage The company specializes in kinetic profiling to accelerate drug discovery, offering high-quality, reproducible kinetic data that helps clients prioritize compounds and optimize medicinal chemistry, which can be positioned to mid- to late-stage discovery teams seeking efficiency gains.

Strategic partnerships A track record of worldwide partnerships across organizations of varying sizes presents a credibility signal for new customers, particularly those needing flexible, early-phase support in PK/PD understanding and data-driven decision making.

Scale-ready services With a focus on fast, scalable screening and speed-to-insight, Enzymlogic’s offerings can be pitched to teams facing tight timelines or large compound libraries who require reliable kinetic data to de-risk candidate selection.

Recognition and validation Past awards and European Commission endorsements (Seal of Excellence, Innovative SME) provide social proof that can ease outreach to potential clients and investors seeking validated technology partners in the biotech and pharmaceutical space.